Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy
02/09/2025 12:40
Sept 2 (Reuters) - Arrowhead Pharmaceuticals ARWR.O said on Tuesday it will receive up to $2 billion from Novartis NOVN.S for an exclusive worldwide license to its experimental therapy that targets neuromuscular conditions such as Parkinson's Disease. (Reporting by Christy Santhosh in Bengaluru; Editing by Krishna Chandra Eluri) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers